A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress) Meeting Abstract
| Authors: | Roeker, L. E.; Alencar, A. J.; Murthy, G. S. G.; Hoffmann, M. S.; Pagel, J. M.; Patel, V.; Pauff, J. M.; Zinzani, P. L.; Le Gouill, S.; Mato, A.; Jurczak, W. |
| Abstract Title: | A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680305081 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS7582 |
| Notes: | Meeting Abstract: TPS7582 -- Meeting also held virtually -- Source: Wos |
